Chantix
(Varenicline Tartrate)Phase 1Small molecule
PfizerVarenicline Tartrate is used to help people quit smoking by reducing cravings and blocking the rewarding effects of nicotine in the brain.[1] Chantix is currently being investigated across 3 indications[3], with its most advanced program in Phase 1.[1]
Chantix is one of 56 small molecule programs targeting Nicotine Dependence. It is currently in Phase 1.
3
Indications
24
Total Trials
3
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Nicotine Dependence
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Ritalin
NovartisApproved
Revia
TevaApproved
Niacor
AbbVieApproved
Aricept
EisaiApproved
Epidiolex
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Rozerem
TakedaApproved
Namenda
AbbVieApproved
Lioresal
NovartisApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Absorption4 trials
Smoking Cessation3 trials
Eye Disease2 trials
Smokers2 trials
Psychiatric Disorder2 trials
11 more indications
Chronic Obstructive Pulmonary Disease1 trial
Smokeless Tobacco1 trial
Single Dose1 trial
Effectiveness1 trial
Tobacco Use Disorder1 trial
Efficacy1 trial
Safety and Efficacy1 trial
Trigeminal Neuralgia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Varenicline Tartrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]